Shares of IDEXX Laboratories (IDXX) soared more than 20% Monday morning after the pet health care company reported better-than-expected second-quarter results and raised its 2025 profit and revenue forecasts.
The Westbrook, Maine-based firm posted GAAP earnings per share of $3.63 on revenue that increased 11% year-over-year to $1.11 billion. Analysts surveyed by Visible Alpha had expected $3.30 and $1.06 billion, respectively.
IDEXX lifted its full-year EPS projection to a range of $12.40 to $12.76 from the prior $11.93 to $12.43. It also raised its revenue outlook to $4.205 billion to $4.280 billion from $4.095 billion to $4.210 billion.
“Our focus on helping veterinarians gain deeper diagnostic insights to inform patient care continues to drive customer loyalty and sets a solid foundation for sustained long-term growth,” IDEXX CEO Jay Mazelsky said.
With today’s surge, IDEXX Laboratories shares have added more than 55% of their value in 2025.
UPDATE—This article has been updated with the latest share price information.